Gary S. Hogge - Feb 11, 2023 Form 4 Insider Report for Lineage Cell Therapeutics, Inc. (LCTX)

Signature
/s/ Grant Harbert, as Attorney-in Fact
Stock symbol
LCTX
Transactions as of
Feb 11, 2023
Transactions value $
-$7,169
Form type
4
Date filed
2/14/2023, 03:15 PM
Previous filing
Mar 11, 2022
Next filing
Mar 10, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LCTX Common Shares, no par value Options Exercise +13K 13K Feb 11, 2023 Direct F1, F2
transaction LCTX Common Shares, no par value Tax liability -$7.17K -5.31K -40.78% $1.35 7.71K Feb 11, 2023 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LCTX Restricted Stock Units Options Exercise $0 -13K -25% $0.00 39.1K Feb 11, 2023 Common Shares 13K $0.00 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis.
F2 Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date of this Report or shares that may be acquired upon the exercise of certain stock options.
F3 Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 13,020 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction.
F4 The Reporting Person was granted RSUs on February 11, 2022 that vested with respect to 25% of the shares subject to the award on February 11, 2023, and the balance will vest in 3 equal annual installments on each anniversary date thereafter.